Benfotiamine-S-Benzoylthiamine-O-monophosphate-DataSheet-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEBenfotiamineCat. No.: HY-17374CAS No.: 22457-89-2Synonyms: S-Benzoylthiamine O-monophosphate分式: CHNOPS分量: 466.45作靶點(diǎn): Reactive Oxygen Species作通路: Immunology/Inflammation; Metabolic Enzyme/Protease; NF-B儲(chǔ)存式: Powder -20C 3 years4C

2、2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 50 mg/mL (107.19 mM)H2O : 0.67 mg/mL (1.44 mM; Need ultrasonic)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 2.1439 mL 10.7193 mL 21.4385 mL5 mM 0.4288 mL 2.1439 mL 4.2877 mL10 mM 0.2144 mL 1.071

3、9 mL 2.1439 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前?qǐng)先配制澄清的儲(chǔ)備液，再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (5.36 mM); Clear solution2. 請(qǐng)依序添加每種溶劑

4、： 10% DMSO 90% (20% SBE-CD in saline)1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemESolubility: 2.5 mg/mL (5.36 mM); Clear solution3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (5.36 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Benfotiamine維素B1的衍物，有抗氧化活性。REFERENCES1. Tarallo S, Beltramo E,

5、 Berrone E, Porta M. Human pericyte-endothelial cell interactions in co-culture models mimicking the diabeticretinal microvascular environment. Acta Diabetol. 2012 Dec;49 Suppl 1:141-51.2. Engelen L, Stehouwer CD, Schalkwijk CG. Current therapeutic interventions in the glycation pathway:Evidence fro

6、m clinical studies.Diabetes Obes Metab. 2012 Dec 26.3. Hurt JK, Coleman JL, Fitzpatrick BJ, et al. Prostatic acid phosphatase is required for the antinociceptive effects of thiamine andbenfotiamine. PLoS One. 2012;7(10):e48562.4. Hans-Peter Hammes, Xueliang Du, Diane Edelstein, et al. Benfotiamine b

7、locks three major pathways of hyperglycemic damage andprevents experimental diabetic retinopathy. Nature Medicine, 2003, 9, 294 - 2995. Loew D. Pharmacokinetics of thiamine derivatives especially of benfotiamine. International Journal of Clinical Pharmacology andTherapeutics, 1996, 34(2):47-506. BenfotiamineMcePdfHeightCaution: Product has not been fully validated for medical applications.For research